ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic

Research output: Contribution to journalReview article

33 Scopus citations

Abstract

ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial for ELND006 was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action. However, this represents another small molecule γ-secretase inhibitor that has failed in clinical trials (semagacestat) (http://newsroom.lilly.com/releasedetail.cfm? releaseid=499794) which raises serious questions regarding this mechanism for the treatment of AD.

Original languageEnglish (US)
Pages (from-to)279-280
Number of pages2
JournalACS Chemical Neuroscience
Volume2
Issue number6
DOIs
StatePublished - Jun 15 2011

Keywords

  • Alzheimer's disease
  • ELND006
  • clinical trials
  • semagacestat
  • γ-secretase

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on ELND006: Another γ-secretase inhibitor fails in the clinic'. Together they form a unique fingerprint.

  • Cite this